United States was AIM ImmunoTech’s largest region in fiscal 2019, bringing in $110.00K of $140.00K (79%).
| Geography | FY 2015 | FY 2016 | FY 2017 | FY 2019 |
|---|---|---|---|---|
| Europe | — | $335.00K | $30.00K | |
| United States | — | — | $110.00K | |
| Us | $92.00K | $102.00K | — | |
| Total | $92.00K | $437.00K | $140.00K |
AIM ImmunoTech brought in $140.00K from its two regions in fiscal 2019, the year ended December 31, 2019. AIM ImmunoTech regrouped these regions after fiscal 2017, so the total does not compare directly with that year's $437.00K. United States was the largest at $110.00K (78.6%), ahead of Europe at $30.00K (21.4%).
AIM ImmunoTech began breaking out Europe in fiscal 2017 and United States in fiscal 2019. AIM ImmunoTech stopped reporting Us as a separate region after fiscal 2017, when it brought in $102.00K.
AIM ImmunoTech (AIM) reports its revenue by geography. In fiscal 2019, United States was its largest region, bringing in $110.00K (78.6% of the total), followed by Europe at $30.00K (21.4%).
United States was AIM ImmunoTech's largest region in fiscal 2019, bringing in $110.00K, or 78.6% of the $140.00K total across its two regions.
Every figure comes from AIM ImmunoTech's annual financial filings, as reported. Each line keeps the name AIM ImmunoTech gives it, and years follow its fiscal calendar.
AIM ImmunoTech's revenue by geography goes back to fiscal 2015, with figures through fiscal 2019. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.